問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of Hematology & Oncology

Digestive System Department

Division of General Internal Medicine

Division of General Surgery

Far Eastern Memorial Hospital (非在職)

Division of Hematology & Oncology

更新時間：2025-02-26

葉坤輝Yeh, Kun-Huei
  • Principal Investigator
  • Clinical Trial Experience (year) -24 years -4 個月

Recruiting Trial

97Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

葉坤輝

List

204Cases

2024-03-01 - 2028-10-10

Phase II

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
7Sites

Not yet recruiting4Sites

Recruiting2Sites

2024-03-01 - 2026-12-31

Phase I

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
3Sites

Recruiting3Sites

2024-04-01 - 2024-05-06

Phase I

-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
2Sites

Terminated2Sites

2024-05-01 - 2031-08-31

Phase I/II

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
4Sites

Recruiting4Sites

2024-05-15 - 2030-12-31

Phase I

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
2Sites

Recruiting2Sites

2024-09-01 - 2032-12-31

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
5Sites

Recruiting5Sites

2026-06-01 - 2032-01-17

Phase III

Not yet recruiting
RASolute 303: A Phase 3 Global, Multicenter, Open-label, Randomized, 3-Arm Study of Daraxonrasib Monotherapy or Daraxonrasib Plus Gemcitabine and Nab-paclitaxel Versus Gemcitabine and Nab-paclitaxel as a First-Line Treatment for Patients With Metastatic Pancreatic Adenocarcinoma

  • Condition/Disease

    Pancreatic Cancer、PDAC - Pancreatic Ductal Adenocarcinoma

  • Test Drug

    錠劑 靜脈輸注液 靜脈輸注液

Participate Sites
5Sites

Recruiting5Sites

2024-10-01 - 2032-12-31

Phase I/II

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
3Sites

Recruiting3Sites

2024-11-01 - 2029-08-31

Phase III

-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
10Sites

Recruiting10Sites

2024-11-01 - 2029-12-31

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
7Sites

Not yet recruiting3Sites

Recruiting4Sites

1 2 3 4 5 6 21
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB